NDA 019668 · Viatris
Cardura
Doxazosin Mesylate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Jun 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Nov 2, 1990
Approved uses
1
Original approval plus efficacy supplements
Registered trials
59
6 Phase 3, 0 recruiting
FAERS reports
35,916
29,638 serious, 3,084 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 24, 2025.
Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been...
Mechanism: Benign Prostatic Hyperplasia (BPH) The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component of BPH is associated with an increase...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 2, 1990 Original approval · Type 1 - New Molecular Entity
4 products under this application
- CARDURA · DOXAZOSIN MESYLATE EQ 4MG BASE · TABLET, ORAL · Prescription · TE AB
- CARDURA · DOXAZOSIN MESYLATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
- CARDURA · DOXAZOSIN MESYLATE EQ 8MG BASE · TABLET, ORAL · Prescription · TE AB
- CARDURA · DOXAZOSIN MESYLATE EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxazosin" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Medical Therapy of Prostatic SymptomsPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00021814 · 3,407 participants · Start Dec 1995 · Primary completion Nov 30, 2001
Drug: Doxazosin; Finasteride and 2 more · For: Prostatic Hyperplasia; Prostatic Hypertrophy, Benign
Sites: La Jolla, California; Aurora, Colorado; New Haven, Connecticut · 17 sites in all
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
- Nephropathy In Type 2 Diabetes and Cardio-renal EventsPivotal-lookingCompleted
University of Campania Luigi VanvitelliAcademic, hospital or other
NCT00535925 · 850 participants · Start Oct 2005 · Primary completion Dec 2011
Drug: SoC therapy; irbesartan and 12 more · For: Diabetic Nephropathy
Sites: Naples, Italy
- Japan Morning Surge-1 StudyPivotal-lookingCompleted
Japan Heart FoundationAcademic, hospital or other
NCT00285519 · 600 participants · Start Aug 2003
Drug: Doxazosin (drug) · For: Hypertension
Sites: Shimotsuke, Japan
- Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1Pivotal-lookingCompleted
Buddhist Tzu Chi General HospitalAcademic, hospital or other
NCT01661621 · 395 participants · Start Aug 2012 · Primary completion Aug 2013
Drug: Detrusitol 4 mg QD; Doxazosin 4 mg QD · For: Bladder Outlet Obstruction
Sites: Hualien City, Taiwan
- Optimum Treatment for Drug-Resistant HypertensionPivotal-lookingStatus unknown
University of CambridgeAcademic, hospital or other
NCT02369081 · 348 participants · Start May 2009 · Primary completion Jul 2015
Drug: Spironolactone; Bisoprolol and 2 more · For: Hypertension, Resistant to Conventional Therapy
Sites: Ayrshire, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 16 sites in all
- Alfuzosin for Medical Expulsion Therapy of Ureteral StonesPivotal-lookingStatus unknown
United States Naval Medical Center, San DiegoFederal agency
NCT00713739 · 240 participants (planned) · Start Jan 2008 · Primary completion Dec 2010
Drug: Alfuzosin; nifedipine and 2 more · For: Kidney Stones
Sites: San Diego, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,987
- fatigue1,755
- dizziness1,719
- diarrhoea1,694
- drug ineffective1,605
- nausea1,490
- hypotension1,309
- acute kidney injury1,268
- headache1,268
- asthenia1,247
- hypertension1,159
- drug interaction1,118
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 687 |
| 2005 | 703 |
| 2006 | 718 |
| 2007 | 747 |
| 2008 | 704 |
| 2009 | 853 |
| 2010 | 1,096 |
| 2011 | 1,351 |
| 2012 | 1,374 |
| 2013 | 1,270 |
| 2014 | 1,597 |
| 2015 | 2,001 |
| 2016 | 2,146 |
| 2017 | 2,066 |
| 2018 | 2,559 |
| 2019 | 2,741 |
| 2020 | 2,104 |
| 2021 | 1,894 |
| 2022 | 1,929 |
| 2023 | 1,951 |
| 2024 | 2,070 |
| 2025 | 1,955 |
| 2026 | 1,399 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cardura (Doxazosin Mesylate)
2024 spending
$384K
Beneficiaries
183
711 claims
Per beneficiary
$2,097
$5.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,159,081 |
| 2021 | $717,905 |
| 2022 | $516,256 |
| 2023 | $465,074 |
| 2024 | $383,733 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, et al. · Lancet 2015 · Comparative Study, Randomized Controlled Trial
- The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.
Skeie-Larsen M, Stave R, Grønli J, et al. · Int J Environ Res Public Health 2022 · Systematic Review, Meta-Analysis
- Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.
Yoosuf BT, Panda AK, Kt MF, et al. · Sci Rep 2024 · Systematic Review, Comparative Study
- Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis.
Tian Z, Vollmer Barbosa C, Lang H, et al. · Cardiovasc Res 2024 · Systematic Review, Network Meta-Analysis
- Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.
Buitenwerf E, Osinga TE, Timmers HJLM, et al. · J Clin Endocrinol Metab 2020 · Multicenter Study, Randomized Controlled Trial
- The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD, Roehrborn CG, Bautista OM, et al. · N Engl J Med 2003 · Clinical Trial, Multicenter Study
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.